sulfur hexafluoride lipid-type a microspheres (Lumason) Report issue

Small molecule Imaging Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
SULFUR HEXAFLUORIDE is a component of LUMASON® (sulfur hexafluoride lipid-type A microspheres). It is an ultrasound contrast agent indicated for use in the heart echocardiography and in ultrasonography of the liver and the urinary tract. The sulfur hexafluoride lipid microspheres are composed of SF6 gas in the core surrounded by an outer shell monolayer of phospholipids with palmitic acid as a stabilizer.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

bri | contrast agent br1 | hexafluoridosulfur | hexafluorosulfur | lumason | sf2 compound | sonovue | sonovue (for the microbubble formulation) | sulfur(6+) fluoride | sulfur difluoride | sulfur fluoride | sulfur hexafluoride | sulfur hexafluoride lipid microsphere | sulfur hexafluoride lipid-type a microspheres | sulfur(vi) fluoride | sulphur hexafluoride

Organizations (38)

Research & Development (38)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (44)

Approved Indications (3)


 

Heart Diseases (approved 2014)

Liver Diseases (approved 2014)

Vesico-Ureteral Reflux (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (44)


 

Abdominal Injuries (Phase 4)

Accidental Falls (Phase 4)

Acute Febrile Encephalopathy (Phase 3)

Appendicitis (Phase 2)

Brain Diseases (Phase 3)

Breast Neoplasms (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Pancreatic Ductal (Phase 2)

Colorectal Neoplasms (Phase 1/Phase 2)

Coronary Artery Disease (Phase 3)

COVID-19 (Phase 3)

Crohn Disease (Phase 4)

Developmental Dysplasia of the Hip (Early Phase 1)

Enterocolitis, Necrotizing (Phase 3)

Eye Diseases (Phase 3)

Fibrosis (Phase 3)

Heart Diseases (Phase 3)

Hemorrhage (Phase 4)

Hereditary Autoinflammatory Diseases (Phase 3)

Hypertension, Pulmonary (Phase 2)

Hypoxia-Ischemia, Brain (Phase 3)

Infant, Premature, Diseases (Phase 3)

Intestinal Diseases (Phase 3)

Ischemic Stroke (Phase 3)

Kidney Transplantation (Phase 1)

Liver Diseases (Phase 4)

Liver Neoplasms (Phase 3)

Lung Diseases (Phase 1/Phase 2)

Lymphedema (Phase 1)

Mitochondrial Diseases (Phase 1)

Mitochondrial Myopathies (Phase 1)

Motor Vehicles (Phase 4)

Neoplasm Metastasis (Phase 4)

Physical Abuse (Phase 4)

Pregnancy (Phase 3)

Prostatic Neoplasms (Phase 3)

Retinal Detachment (Phase 3)

Stroke (Phase 3)

Tetralogy of Fallot (Phase 1/Phase 2)

Traumatology (Phase 4)

Urinary Tract Infections (Phase 2)

Vesico-Ureteral Reflux (Phase 4)

Vitreoretinopathy, Proliferative (Phase 3)

Wet Macular Degeneration (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 53
  • # of Trial Organizations: 38

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue